Aurinia Pharmaceuticals Presents New Analysis of Lupkynis at EULAR 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Aurinia Pharmaceuticals announced that a new analysis of the AURORA 1 Phase 3 study of Lupkynis in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology, EULAR, 2026 Congress. This new analysis on the safety population of 356 patients indicates that Lupkynis was associated with a statistically significant 53% reduction in the risk of renal-related event or death. Hazard ratios favored treatment with Lupkynis for the following individual components of the composite endpoint: death, treatment failure and worsening proteinuria.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AUPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AUPH
Wall Street analysts forecast AUPH stock price to rise
6 Analyst Rating
3 Buy
3 Hold
0 Sell
Moderate Buy
Current: 16.140
Low
13.00
Averages
16.50
High
21.00
Current: 16.140
Low
13.00
Averages
16.50
High
21.00
About AUPH
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aurinia Pharmaceuticals CEO Acquires Shares Worth $12.5 Million
- Share Acquisition: Aurinia Pharmaceuticals CEO Kevin Tang acquired 814,606 common shares through affiliated entities between May 29 and June 2, 2026, for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share, indicating strong confidence in the company's future prospects.
- Ownership Change: This purchase represents a 6.66% increase in Tang's holdings, although his direct ownership remains zero post-transaction, reflecting a strategic focus on the company's governance and potential growth through investment funds.
- Sales Growth: Aurinia's Lupkynis drug saw a 24% year-over-year sales increase in Q1 2026, reaching an annualized $310 million, and with the recent long-term study results, sales could exceed $1 billion annually in a few years, solidifying the company's position in the autoimmune disease treatment market.
- Profitability Improvement: Aurinia reported a 48% year-over-year increase in net income for Q1 2026, reaching an annualized $137.6 million, and as profits rise, Tang's acquisition may attract more investor interest, potentially driving the stock price higher.
See More
Aurinia CEO Kevin Tang Acquires 814,606 Shares
- Significant Acquisition: Aurinia Pharmaceuticals CEO Kevin Tang purchased 814,606 common shares between May 29 and June 2, 2026, with a total transaction value of approximately $12.5 million, indicating strong confidence in the company's future prospects.
- Indirect Holdings Increase: While Tang's direct ownership remains zero post-transaction, his indirect holdings have risen to 13,044,106 shares, and he retains indirect exposure to an additional 10,000 shares via outstanding short put options, potentially increasing beneficial ownership further.
- Sales Growth Potential: Aurinia's LUPKYNIS drug saw a 24% year-over-year sales increase in Q1 2026, reaching an annualized $310 million, and with the release of long-term clinical trial results, sales could exceed $1 billion in the coming years, further solidifying the company's market position.
- Profitability Improvement: Aurinia reported a 48% year-over-year increase in net income for Q1 2026, reaching an annualized $137.6 million, making it particularly wise for investors to follow the CEO's lead in increasing their Aurinia positions, reflecting optimistic market expectations for future growth.
See More
Director Paul J. Fribourg Acquires 273,500 Shares of IFF
- Director's Share Purchase: Paul J. Fribourg, a director at International Flavors & Fragrances, purchased 273,500 shares at $74.29 each for a total of $20.32 million on Monday, indicating strong confidence in the company's future, which may enhance market trust in IFF.
- Stock Price Increase: On Wednesday, IFF's stock rose approximately 2.5%, reflecting positive market reaction to Fribourg's purchase, which could attract more investor interest and further drive up the stock price.
- CEO's Investment in Aurinia: CEO Kevin Tang bought 814,606 shares of Aurinia Pharmaceuticals at $15.29 each for a total of $12.46 million on Tuesday, demonstrating optimism about Aurinia's future potential, which may boost market confidence in the company.
- AUPH Stock Performance: Aurinia Pharmaceuticals saw a 3.6% increase on Wednesday, with Tang's purchase contributing to a 4.6% rise at the day's peak, indicating optimistic market expectations for its future performance and potentially attracting more investor attention.
See More
Tang Capital Acquires Shares of Aurinia Pharmaceuticals
- Share Acquisition: Tang Capital Management announced on Tuesday the acquisition of 206,005 common shares of Aurinia Pharmaceuticals at a price of $15.28 per share, totaling $3.1 million, reflecting strong investment confidence in the company.
- Increased Ownership: Following this purchase, Tang Capital Management beneficially owns 13,044,106 common shares, representing approximately 10% of Aurinia's issued shares, thereby enhancing its influence within the company.
- Financial Performance: Aurinia Pharmaceuticals recently reported a GAAP EPS of $0.25, beating estimates by $0.05, with revenue of $77.7 million exceeding expectations by $0.72 million, indicating the company's competitive position and profitability in the market.
- Strategic Opportunities: Aurinia is pursuing the acquisition of Kezar Life Sciences, demonstrating its strategic intent to expand its business, which could provide new growth momentum in the future.
See More
Aurinia Reports 23% Revenue Growth in Q1
- Revenue Growth Highlight: Aurinia reported first-quarter revenue of $77.7 million, a 24% year-over-year increase that surpassed Wall Street's expectations of $77 million, indicating strong market performance despite a stock price drop due to information scarcity.
- Lupkynis Sales Surge: The 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, was the primary driver of revenue growth, reflecting robust market demand for this critical therapy.
- Leadership Change Impact: Following a significant leadership overhaul in March, with Kevin Tang appointed as CEO, investor unease grew due to the absence of an earnings call and limited updates on clinical trials, resulting in a more than 10% drop in stock price in a single day despite positive earnings.
- Future Outlook: The company reiterated its FY2026 revenue guidance of $315 million to $325 million, representing an 11% to 15% year-over-year growth, demonstrating confidence in future growth prospects despite market volatility.
See More
Aurinia Pharmaceuticals Reports Q1 Earnings Growth
- Earnings Growth: Aurinia Pharmaceuticals reported a first-quarter net income of $34.36 million, translating to an EPS of $0.25, which marks a significant increase from last year's $23.34 million and $0.16 EPS, indicating strong market performance.
- Revenue Increase: The company's revenue for the quarter reached $77.71 million, up 24.4% from $62.47 million last year, driven primarily by increased market acceptance of new products, reinforcing its position in the biopharmaceutical sector.
- Full-Year Guidance: Aurinia has provided a full-year revenue guidance of $315 million to $325 million, reflecting confidence in future market demand and potentially attracting more investor interest.
- Market Reaction: With the improved earnings and positive outlook guidance, Aurinia's stock is likely to gain favor among investors, further enhancing its competitiveness and market share in the biopharmaceutical industry.
See More
Aurinia Pharmaceuticals CEO Acquires Shares Worth $12.5 Million
- Share Acquisition: Aurinia Pharmaceuticals CEO Kevin Tang acquired 814,606 common shares through affiliated entities between May 29 and June 2, 2026, for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share, indicating strong confidence in the company's future prospects.
- Ownership Change: This purchase represents a 6.66% increase in Tang's holdings, although his direct ownership remains zero post-transaction, reflecting a strategic focus on the company's governance and potential growth through investment funds.
- Sales Growth: Aurinia's Lupkynis drug saw a 24% year-over-year sales increase in Q1 2026, reaching an annualized $310 million, and with the recent long-term study results, sales could exceed $1 billion annually in a few years, solidifying the company's position in the autoimmune disease treatment market.
- Profitability Improvement: Aurinia reported a 48% year-over-year increase in net income for Q1 2026, reaching an annualized $137.6 million, and as profits rise, Tang's acquisition may attract more investor interest, potentially driving the stock price higher.
See More
Aurinia CEO Kevin Tang Acquires 814,606 Shares
- Significant Acquisition: Aurinia Pharmaceuticals CEO Kevin Tang purchased 814,606 common shares between May 29 and June 2, 2026, with a total transaction value of approximately $12.5 million, indicating strong confidence in the company's future prospects.
- Indirect Holdings Increase: While Tang's direct ownership remains zero post-transaction, his indirect holdings have risen to 13,044,106 shares, and he retains indirect exposure to an additional 10,000 shares via outstanding short put options, potentially increasing beneficial ownership further.
- Sales Growth Potential: Aurinia's LUPKYNIS drug saw a 24% year-over-year sales increase in Q1 2026, reaching an annualized $310 million, and with the release of long-term clinical trial results, sales could exceed $1 billion in the coming years, further solidifying the company's market position.
- Profitability Improvement: Aurinia reported a 48% year-over-year increase in net income for Q1 2026, reaching an annualized $137.6 million, making it particularly wise for investors to follow the CEO's lead in increasing their Aurinia positions, reflecting optimistic market expectations for future growth.
See More
Director Paul J. Fribourg Acquires 273,500 Shares of IFF
- Director's Share Purchase: Paul J. Fribourg, a director at International Flavors & Fragrances, purchased 273,500 shares at $74.29 each for a total of $20.32 million on Monday, indicating strong confidence in the company's future, which may enhance market trust in IFF.
- Stock Price Increase: On Wednesday, IFF's stock rose approximately 2.5%, reflecting positive market reaction to Fribourg's purchase, which could attract more investor interest and further drive up the stock price.
- CEO's Investment in Aurinia: CEO Kevin Tang bought 814,606 shares of Aurinia Pharmaceuticals at $15.29 each for a total of $12.46 million on Tuesday, demonstrating optimism about Aurinia's future potential, which may boost market confidence in the company.
- AUPH Stock Performance: Aurinia Pharmaceuticals saw a 3.6% increase on Wednesday, with Tang's purchase contributing to a 4.6% rise at the day's peak, indicating optimistic market expectations for its future performance and potentially attracting more investor attention.
See More
Tang Capital Acquires Shares of Aurinia Pharmaceuticals
- Share Acquisition: Tang Capital Management announced on Tuesday the acquisition of 206,005 common shares of Aurinia Pharmaceuticals at a price of $15.28 per share, totaling $3.1 million, reflecting strong investment confidence in the company.
- Increased Ownership: Following this purchase, Tang Capital Management beneficially owns 13,044,106 common shares, representing approximately 10% of Aurinia's issued shares, thereby enhancing its influence within the company.
- Financial Performance: Aurinia Pharmaceuticals recently reported a GAAP EPS of $0.25, beating estimates by $0.05, with revenue of $77.7 million exceeding expectations by $0.72 million, indicating the company's competitive position and profitability in the market.
- Strategic Opportunities: Aurinia is pursuing the acquisition of Kezar Life Sciences, demonstrating its strategic intent to expand its business, which could provide new growth momentum in the future.
See More
Aurinia Reports 23% Revenue Growth in Q1
- Revenue Growth Highlight: Aurinia reported first-quarter revenue of $77.7 million, a 24% year-over-year increase that surpassed Wall Street's expectations of $77 million, indicating strong market performance despite a stock price drop due to information scarcity.
- Lupkynis Sales Surge: The 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, was the primary driver of revenue growth, reflecting robust market demand for this critical therapy.
- Leadership Change Impact: Following a significant leadership overhaul in March, with Kevin Tang appointed as CEO, investor unease grew due to the absence of an earnings call and limited updates on clinical trials, resulting in a more than 10% drop in stock price in a single day despite positive earnings.
- Future Outlook: The company reiterated its FY2026 revenue guidance of $315 million to $325 million, representing an 11% to 15% year-over-year growth, demonstrating confidence in future growth prospects despite market volatility.
See More
Aurinia Pharmaceuticals Reports Q1 Earnings Growth
- Earnings Growth: Aurinia Pharmaceuticals reported a first-quarter net income of $34.36 million, translating to an EPS of $0.25, which marks a significant increase from last year's $23.34 million and $0.16 EPS, indicating strong market performance.
- Revenue Increase: The company's revenue for the quarter reached $77.71 million, up 24.4% from $62.47 million last year, driven primarily by increased market acceptance of new products, reinforcing its position in the biopharmaceutical sector.
- Full-Year Guidance: Aurinia has provided a full-year revenue guidance of $315 million to $325 million, reflecting confidence in future market demand and potentially attracting more investor interest.
- Market Reaction: With the improved earnings and positive outlook guidance, Aurinia's stock is likely to gain favor among investors, further enhancing its competitiveness and market share in the biopharmaceutical industry.
See More
